Testosterone Treatment and the Risk of Prostate Adverse Events

Endocrinol Metab Clin North Am. 2022 Mar;51(1):123-131. doi: 10.1016/j.ecl.2021.11.011. Epub 2022 Feb 8.

Abstract

Hypogonadism is a common clinical condition affecting men, with older men having an increased incidence. Clinicians (endocrinologists and urologists) who may be involved in providing testosterone therapy should be familiar with the effects of testosterone on the prostate. Before initiating testosterone therapy, physicians and patients should partake in shared decision-making, including pretreatment testing, risks and benefits of testosterone therapy relating to benign prostatic hyperplasia and lower urinary tract symptoms, a discussion on prostate cancer in those who have not been diagnosed with malignancy, and a thorough discussion with patients who may have a previous diagnosis of prostate cancer.

Keywords: Benign prostatic hyperplasia (BPH); Hypogonadism; Prostate cancer (PCa); Testosterone (T).

Publication types

  • Review

MeSH terms

  • Aged
  • Humans
  • Hypogonadism* / chemically induced
  • Hypogonadism* / drug therapy
  • Lower Urinary Tract Symptoms* / chemically induced
  • Lower Urinary Tract Symptoms* / drug therapy
  • Lower Urinary Tract Symptoms* / pathology
  • Male
  • Prostate / pathology
  • Prostatic Hyperplasia* / chemically induced
  • Prostatic Hyperplasia* / drug therapy
  • Prostatic Hyperplasia* / pathology
  • Testosterone / adverse effects

Substances

  • Testosterone